Respiratory Disorders: Wk 3 Flashcards

1
Q

asthma definition

A

-Hyper responsiveness to stimuli that produce bronchoconstriction
-Stimuli include cold air, exercise, allergens and emotional stress
-Airway inflammation and edema
-Resulting from release of various mediators from mast cells, eosinophils, macrophages, etc.
-Mediators include histamine, adenosine, bradykinin, leukotrienes and prostaglandins
-chronic inflammatory disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

asthma causes of obstruction and sx

A

-Airway obstruction results from:
- bronchial inflammation
- smooth muscle constriction
- obstruction of the lumen with mucus, inflammatory cells and epithelia debris

-Symptoms of obstruction: dyspnea, coughing, wheezing, headache, tachycardia, syncope (fainting), diaphoresis (excessive sweating), pallor (paleness) and cyanosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

COPD

A

COPD
-General symptoms: dyspnea on exertion (DOE), cough, acute exacerbations w/ wheezing and dyspnea
-Types of COPD:
-Chronic Bronchitis: chronic productive cough x 3 months (in 2 successive years)
-Emphysema: abnormal enlargement of airspaces; destruction of airspace walls -> barrel chest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

asthma vs COPD

A

-asthma: sensitizing agent -> asthmatic airway inflammation, CD4+ T lymphocytes, eosinophils -> -completely reversible

-COPD: noxious agent -> COPD airway inflammation, CD8+ T lymphocytes, macrophages, neutrophils
-completely irreversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

asthma: bronchodilators

A

-beta agonists
-Epinephrine
-Anticholinergics
-Theophylline (xanthine dervatives)

“you can BEAT asthma - its reversible”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

asthma: anti-inflammatory agents

A

-Omalizumab (Xolair)
-Glucocorticosteroids **
-Mast cell stabilizers
-Leukotriene inhibitors

“OMG Luca(R)io has asthma”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

COPD: bronchodilators

A

-Beta 2 agonists
-Anticholinergics
-Theophylline – for refractory cases

“you can’t BEAT COPD -> irreversible so its just a BATtle”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

COPD: anti-inflammatory

A

-Systemic glucocorticosteroids – for acute exacerbations
-Inhaled glucocorticosteroids – for chronic management
-Roflumilast (Daliresp) – PDE 4 inhibitor (new class of drug)

“SIR -> Lucario’s boss”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the only agents that can counteract an acute asthmatic attack?

A

-Short acting beta2 agonists : SABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

________are less useful in asthma, better for COPD

A

Anticholinergics: better for COPD and emphysema/chronic bronchitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Theophylline

A

used on long term basis to prevent bronchoconstriction in asthma and emphysema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

metered dose inhaler (MDI)

A

Correct use: shake, full exhale, start inhaling slowly and then press MDI, hold breath for 5-10
seconds
-Need to wait 1 minute between doses, 5 minutes between different drugs so drug can take
effect and 2nd dose can get deeper
-simple MDI- hard to use
-with aerochamber- easier to use
-MDI, aerochamber, facemask - mask pieace
-portable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

dry powder inhaler

A

-Inside there is a capsule that is punctured when you press, then breathe in
-Need to breathe in quickly (compared to MDI where you breathe in slowly) -> BAD for COPD pts that have bad inspiratory effort

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Nebulizer machine

A
  • easy to use
  • It atomizes the drug, makes it smaller so it can get deeper into the lung for better treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

mixed non-selective bronchodilators

A

-Epinephrine (alpha1- increased BP, beta1- increase HR, B2 - bronchodilation)
-Uses: Can be used for asthma, but B2 agonists are preferred
-Examples:
-Epinephrine (SQ, IM, IV) (C)
-Epinephrine inhaled (Primatene mist)
-Racemic epinephrine (nebulized) – more for bronchospasms, croup cough)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

bronchodilators: non-selective beta agonists

A

-Have some effect on beta1 receptors also
-Cardiac effects

-drug examples:
-Isoproterenol
-Pirbuterol

“daniel IP is non-selective -> thats why he went to USC instead of UCLA”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

bronchodilators: beta 2 selective agonists

A

-Specific for beta2 receptors
-less cardiac stimulation
-selectivity is limited as doses become higher, resulting in HR and contractility

-albuterol: MC*
-Terbutaline
-Levabuterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

bronchodilators: beta 2 selective agonists: short acting SABA

A

-acute attack, use PRN
-Uses: Asthma, exercise induced asthma (EIA), COPD
-Examples: albuterol, levalbuterol, terbutaline
-Albuterol
-MDI, neb, PO (tabs or solution)
-Combined w/ ipratropium (Combivent inhaler, Duoneb nebulizer)
-Levalbuterol - kids
-Terbutaline (Brethine) (C) PO, INJ -> Inhaler form (Bricanyl) – not available in US

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

bronchodilators: beta 2 selective agonists- longer acting LABA

A

-maintenance medication
-Uses: Asthma, COPD
-Given BID or q12h , NOT PRN, NOT for acute attacks
-Examples: Salmeterol, Formoterol, Arformoterol
-Salmeterol (Serevent) (C) DPI -> w/ fluticasone (Advair DPI(MY MOM), MDI)
-Formoterol
-Arformoterol (neb - new drug for COPD)

LAba = SF(A)

LA and SF are cool cities to go to
-salmon
-fomo
-alfomo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ADRs for all beta agonists

A

-Local: dry irritated throat, cough, bad taste
-Systemic:
- CNS stimulation (insomnia, excitability, tremor)
- cardiac stimulation
- hypotension (depending on degree of beta 2 stimulation in vasculature)
- Hyperglycemia and hypokalemia also occur secondary to beta 2 agonist activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

bronchodilators: anticholinergics asthma vs COPD use

A

Asthma: use in combo w/ beta 2 agonists -> NOT PRN

For COPD – may be used as PRN (per GOLD guidelines), and can be used as monotherapy

Rhinitis tx as well

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

bronchodilators: anticholinergics agents

A

-Ipratropium:
-short acting anticholinergic
- asthma:use in combo with beta 2 agonist (albuterol); NOT PRN
-For COPD: PRN or monotherapy
-ADRs – CNS, palps, bitter taste, cough

-Tiotropium:
-long acting anticholinergic – QD = better compliance
-Longer DOA
-Very expensive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

bronchodilators: xanthine derivatives

A

-Uses: Asthma, Refractory COPD
-MOA: Phosphodiesterase inhibitor causing bronchodilation and some anti-inflammatory effects

-Examples:
-Theophylline oral (Theodur, Slo-Bid)- needs to be monitored because of TI
-Aminophylline IV

-phylline= xanthine derivatives

“Xanthine is sweet - sweet soup = PHO(sPHOdiesterase inhibitor)

24
Q

Xanthine derivatives ADR and precautions

A

-Precautions: Produces high amount of cardiovascular and CNS stimulation and diuresis (increased urine output)
-Drug-drug interactions (DDIs): Substrate of CYP1A2 (liver enzyme), many DDI
-Narrow therapeutic index (TI) must monitor levels
-ADRs: LOTS -> not used much
-GI effects: nausea/vomiting, diarrhea, epigastric pain
-CNS effects: insomnia, agitation, dizziness, seizures
-CVS effects: tachycardia, PVCs -> palpitations

“think xanthine gum - sweetener for coffee -> coffee has lots of side effects and drug interactions
- heart, gi, CNS - makes it so you can’t sleep and agitated + dizzy -> seizures”
- diuresis:caffeine makes you want to pee more

25
Q

glucocorticosteroids

A

-Work in bronchioles to reduce inflammation
-Cornerstone of TX in pts with persistent asthma
-inhaled forms:long term maintenance tx of asthma and COPD
-PO and INJ forms: management of exacerbations
-Used in Stage 3 and Stage 4 COPD + persistent asthma on long term basis
-NOT for asthma acute attacks

-Max response requires 8 weeks to develop
-Reduce # and severity of Sx and decrease need for rescue inhalers (short-acting B2 agonists)

26
Q

glucocorticosteroids: ADRs

A

-most efficacious anti-inflammatory agents BUT have greatest potential for ADRs
-Inhalation form minimizes systemic ADRs, but can occur
-ADRs (inhaled form):THRUSH
- excessive deposition of drug in mouth and upper airway leading to thrush
-Local irritation, cough, headache, URTI, nasal congestion, and pharyngitis may occur

-ADRs systemic):
-Concern of suppression of growth in children
- cushings ds

27
Q

inhaled glucocorticosteroids

A

used for long term maintenance of persistent asthma and COPD; NOT for acute attacks

-Beclomethasone
-Budesonide
-Flunisolide
-Fluticasone
-Mometasone - easiest to take-> once a day
-Triamcinolone
-Ciclesonide

-For patients using multiple inhalers:
- give beta2 agonist 1st
- anticholinergic 2nd
- steroid last, rinse after use -> everything else will work better once you open up with a beta 2 agonist

“Beautiful Butterflies Flutter Freely, Making Terrific Circles” (7)

28
Q

mast cell stabilizers

A

-MOA: stabilizes plasma membrane of mast cells and eosinophils -> prevent degranulation and release of histamine, leukotrienes and other mediators -> reduce inflammation
-Uses: proophylax Asthma + EIA; NOT used to treat COPD

MAST cEll stabilizer: Mast cells + Eosinophils
-Not used for acute attacks, MUST use prophylactically (maintenance therapy);

-ADRs – local irritation, bad taste, cough & bronchospasm

-Examples: “-CROM” = mast
-Cromolyn
-Nedocromil

29
Q

systemic glucocorticosteroids

A

-Used for short course “burst” therapy and for asthma or COPD exacerbations **

-Examples:
-Prednisone (Deltasone)
-Methylprednisolone (Medrol,Solumedrol)
-Prednisolone
-Hydrocortisone sodium succinate
-Dexamethasone

30
Q

leukotriene inhibitors

A

-Leukotriene = arachidonic acid metabolite and inflammatory mediator
-Leukotriene receptors mediate:
-Airway inflammation
-Edema
-Bronchoconstriction
-Secretion of thick, viscous mucous
-thus -> Leukotriene inhibitors can reduce airway inflammation and edema, produce bronchodilation and reduce the secretion of thick viscous mucous
-Leukotriene inhibitors subdivided into two categories:
-1. Leukotriene receptor blockers
-2. Lipoxygenase inhibitors

31
Q

leukotriene receptor blockers (LRBs)

A

-MOA: Block leukotriene receptor which reducs leukotriene activity = decreased airway inflammation
-Uses:
- mild-moderate persistent asthma
- seasonal and allergic rhinitis
- NOT for COPD
-NOT for acute Treatment; often used in conjunction w/ beta2 adrenergic agonists

-May take weeks to see benefit: improved pulm fxn, control of Sx, reduction in attacks, reduction in airway inflammation

-Examples: LUKAST
-Zafirlukast
-Montelukast

32
Q

LRB: ADRs and drug interactions

A

ADRs – minimal as a class:

Zafirlukast:
- ADR: fever, malaise, peripheral neuropathy (28%), rash, GI disturbances
- CYP450 enzyme inhibitor - increased levels of ASA, warfarin and theophylline

Montelukast:
- ADR: Headache (18%)
-Drug Interactions: no dose adjustments needed

33
Q

Lipooxygenase inhibitor MOA + PK considerations

A

-MOA: inhibits 5-lipoxygnease enzyme ->decreases production of leukotrienes
-Uses:
- mild-moderate persistent asthma
- Not for COPD

Pharmacokinetic considerations:
- short T1/2 (half-life)
- administered ACHS (4 x’s a day, with meals and at bedtime)

34
Q

Zileuton contraindications

A

**Do not use in pts with active liver disease (LFTs > 3X ULN)

Precaution:pts. with history of liver disease or alcoholic cirrhosis

35
Q

Zileuton ADR + DDI

A

-ADRs
- CNS effects (headache in up to 25% of pts)
- flu like Sx
- dyspepsia
- increase LFTs

CI: pts with active liver ds (caution with alcoholic cirrhosis and past hx of liver ds)

-DDI: CYP450 enzyme inhibitor
- increased levels Beta Blockers, theophylline and warfarin levels

“ZiLEU gives you the FLU + headaches; Leu = increased LFTs”

36
Q

age considerations for leukotriene inhibitors

A

-Zafirlukast (Accolate)- can use in kids over 5 y.o
-Montelukast (Singulair)- can use in kids over 12 months old
-Zileuton (Zyflo)- can use in kids over 12 y.o.
-As a Class – not effective in everyone, but generally better ADRs than steroids

37
Q

What do you treat eosinophilic asthma?

A
  • Benralizumab (SQ, 12+ yrs)
  • Mepolizumab (SQ, 12+ yrs)
    -Reslizumab (IV, 18+ yrs)

-type: IL-5 antagonist, monoclonal antibody (-mab)
- action: decrease eosinophils (IgG1 kappa)
-NOT FOR COPD *

“BMR - eosinophillic asthma”

38
Q

eosinophilic asthma drugs ADRS and concern

A

ADR:
- general: Headache, local injection site reactions
- oropharyngeal pain (Reslizumab)
- pharyngitis (Benralizumab)

main concern: risk for anaphylactic reaction

39
Q

omalizumab MOA + indication

A

-type: IgE blocker monoclonal antibody
- inhibits IgE binding on mast cells and basophils -> decreased activation and release of inflammatory mediators

-indication:
- Moderate to severe asthma in patients ≥6 yrs of age with a positive skin test or in vitro reactivity to a perennial aeroallergen
- chronic idiopathic urticaria in patients ≥12 yrs of age who fail antihistamines
-NOT for COPD

-Dosing: SQ

40
Q

omalizumab precaution + ADR

A

-Precautions: Anaphylaxis risk
-ADRs: Anaphylaxis (0.2%), local injection site reactions, CNS effects (headache, dizziness), arthralgias, pain

41
Q

roflumilast

A
  • type: PDE4 inhibitor: a major cAMP -metabolizing enzyme found in inflammatory cells, which is involved in promoting the pathogenesis of COPD
  • decreases inflammation and promotes smoooth muscle relaxation

Indications:
- decrease the risk of exacerbations in pts with severe COPD
- Add-on therapy to bronchodilators
-NOT for asthma

-Dosing: oral (PO) daily

42
Q

roflumilast contraindications and ADR

A

-Contraindication: pts with Moderate-severe liver dysfunction
-Precautions: neuropsychiatric ADRs, WEIGHT LOSS **

ADRs:
-GI** (nausea, diarrhea, ab. pain, decreased appetite, WEIGHT LOSS**
- neuropsychiatric: dizziness, headache, insomnia

“RO has the stomach FLU - lost a bunch of weight -> nausea, diarrhea; think of the O as the stomach and it progressively shrinks because of weight loss”

43
Q

Classifying asthma: intermittent

A

Intermittent asthma:
-Use inhaled SABA PRN: less than 2 days/wk
-nighttime awakening: less than 2 days/month
- symptoms: less than 2 days /wk
- interference with normal activity: none
-Lung function: normal
- recommended step 1 for initiation tx

-Increased use of short acting beta2-agonists may indicate the need to initiate or increase long-term or maintenance tx

44
Q

Persistent asthma classification

A

-Persistent asthma (mild, moderate or severe):
-require use of SABA PRN in addition to long-term or maintenance treatment. Use stepwise approach to determine the maintenance treatment

general ranges: as it becomes more severe -> worser components of severity
-Use inhaled SABA PRN: over 2 days/wk to daily to several times/daily
-nighttime awakening: over 4 days/month
- symptoms: over 2 days /wk to daily to several times/day
- interference with normal activity: minor, some, extremely limited
-Lung function: affected

Recommended for initiation tx:
- step 2: mild persistent
- Step 3-4: moderate persistent
- step 4-6: severe persistent

45
Q

asthma management goal of therpy

A

-Goals of Therapy:
-1) Reduce Impairment:
-Minimal or no chronic symptoms day or night
-Minimal use (< 2x per week) of inhaled short acting beta2 agonist (SABA)
-Maintain (near) normal pulmonary function
-No limitations on activity; no school/work missed
-Meet patients’ and families expectations of and satisfaction with asthma care
-2) Reduce Risk:
-Prevent exacerbations and minimize ED visits and hospitalizations
-Prevent loss of lung function
-Minimal or no ADRs from drugs

46
Q

asthma management (pts > 12 y.o.): classifying asthma

A

asthma management (pts > 12 y.o.): classifying asthma
-classification based on:
- symptoms
- nighttime awakening
- use of SABA PRN for symptom control
- interference with normal activity
- lung function
-Classification is either Intermittent or Persistent (mild, mod, severe):

47
Q

stepwise approach used to treat asthma

A

-Step 1 (intermittent)
-Step 2 (mild persistent)
-Step 3 - 4 – moderate persistent
-Step 4 - 6 – severe persistent
-Provides general guidelines – not specific RX
-A rescue course of systemic corticosteroids may be needed at any time and at any step

-Step 1: SABA PRN
-Step 2: Low-dose inhaled corticosteroid (ICS)
-Step 3: Low dose ICS + LABA
-Step 4: Medium dose ICS + LABA
-Step 5: High dose ICS + LABA
-Step 6: High dose ICS + LABA + oral steroid

48
Q

asthma management (pts >12yo): education

A

-teach self management
-Teach about controlling environmental factors
-Review administration techniques and compliance
-Use of written plans

49
Q

goals of COPD management

A

-Prevent and decrease symptoms (esp dyspnea)
-Reduce the frequency and severity of exacerbations
-improve health status and exercise capacity

50
Q

COPD management guidelnes based on stage

A

-all stages- avoidance of risk factors, receive influenza and pneumococcal vaccine
-stage 1- very mild COPD with FEV1 about 80%/normal- short acting bronchodilators PRN
-stage2- moderate COPD with FEV1 50-80%- regular tx with 1 or more long acting bronchodilators, short acting bronchodilators PRN, rehabilitation
-stage 3- severe emphysema with FEV1 30-50% of normal- same as stage 2 + inhaled glucocorticosteroids
-stage 4- very severe COPD with lower FEV1 than stage 3 or those with stage 3 FEV1 and low blood oxygen levels- same as stage 3, tx of complications, long term O2 therapy, surgery

51
Q

classification of airflow limitation severity in COPD

A

-GOLD 1- mild - FEV1 >= 80%
-GOLD 2 moderate- FEV1 50-79%
-GOLD 3- severe- 30% <= FEV1 < 50%
-GOLD 4- very severe- FEV1 < 30%

52
Q

treatment based on GOLD

A

Group A: bronchodilator
Group B: LABA , then + LAMA if still have symptoms

Group C: LAMA, then LAMA + LABA or LABA + ICS if still have symptoms
Group D: LAMA + LABA or LABA + ICS, then LAMA + LABA + ICS if still having problems

53
Q

education- proper use of inhalers

A

MDIs: shake before use, to prime: drug delievered via propellant- can use spacer to administer

DPIs: No shaking or priming, dry powder inside no propellants, drug delievered by force of breathin, no spacer

-Proper storage essential – avoid extreme heat or cold
-Store at room temperature
-Pts should keep track of # of puffs or # of days using each inhaler
-Some DPIs have counters on them
-Float test doesn’t work.

54
Q

education- proper use of inhalers: administration technique

A

education- proper use of inhalers: administration technique
-Take cap off inhaler (shake if MDI)
-Breathe out all the way
-For MDI - Start breathing in SLOWLY through mouth, THEN press down on the inhaler
-For DPI – put mouthpiece to lips and breathe in QUICKLY.
-Hold your breath and count to 10 slowly (if you can)
-If using 2 puffs – wait one minute between puffs
-If using a different inhaled drug, wait 5 minutes between drugs
-Use bronchodilators first and steroids last
-Rinse and spit after steroid use

55
Q

in the pipeline for asthma/COPD: PDE-4 inhibitors

A

-Decrease inflammation and promote smooth muscle relaxation
-cilomilast under investigation for the management of both asthma and COPD
-Roflumilast recently approved for COPD
PDE-4 inhibitors

“milast = PDE-4 inhibitors”

56
Q

in the pipeline for asthma/COPD: antiproteases

A

Under investigation for alpha-1 antitrypsin deficiency in emphysema